MAP2K7 and metastatic melanoma: To determine if MEK inhibition prevents VS-5584-induced ERK activation, we treated PDAC cell lines BxPC-3 and HPAC with VS-5584 and the MEK inhibitor GSK1120212 (approved by the US FDA for the treatment of metastatic melanoma) alone or in combination.